Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?
Simmet, V
Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials? [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 11 2019 - 1751-1759 p. digital
Publication Type: Journal Article; Review
1569-8041
10.1093/annonc/mdz286 doi
Antineoplastic Agents, Immunological--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
B7-H1 Antigen--antagonists & inhibitors
CTLA-4 Antigen--antagonists & inhibitors
Clinical Trials, Phase I as Topic--standards
Dose-Response Relationship, Drug
Humans
Maximum Tolerated Dose
Neoplasms--drug therapy
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Protein Kinase Inhibitors--administration & dosage
Research Design--standards
Treatment Outcome
Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials? [electronic resource] - Annals of oncology : official journal of the European Society for Medical Oncology 11 2019 - 1751-1759 p. digital
Publication Type: Journal Article; Review
1569-8041
10.1093/annonc/mdz286 doi
Antineoplastic Agents, Immunological--administration & dosage
Antineoplastic Combined Chemotherapy Protocols--administration & dosage
B7-H1 Antigen--antagonists & inhibitors
CTLA-4 Antigen--antagonists & inhibitors
Clinical Trials, Phase I as Topic--standards
Dose-Response Relationship, Drug
Humans
Maximum Tolerated Dose
Neoplasms--drug therapy
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Protein Kinase Inhibitors--administration & dosage
Research Design--standards
Treatment Outcome